Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

94 recalls · Class III, newest first

Class III · Low risk

Brimonidine Tartrate Opthalmic Solution 0.2%

Failed Impurities/Degradation Specification: There is a slow leaching process from the product label on the bottle which may impact the product over the shelf life.

Terminated Impurity / degradation Somerset Therapeutics LLC NDC 70069-232-01 D-1374-2020
Class III · Low risk

Brimonidine Tartrate Opthalmic Solution 0.2%

Failed Impurities/Degradation Specification: There is a slow leaching process from the product label on the bottle which may impact the product over the shelf life.

Terminated Impurity / degradation Somerset Therapeutics LLC NDC 70069-231-01 D-1373-2020
Class III · Low risk

Clonidine Hydrochloride Tablets

Failed Impurities/Degradation Specifications: potential migration of benzophenone at very low level into the product from container.

Terminated Impurity / degradation Unichem Pharmaceuticals USA INC NDC 29300-135-01 D-1291-2020
Class III · Low risk

Lamotrigine Tablets

Presence of Foreign Substance visually consistent with the silica granules present in the desiccant packs utilized during storage of the product.

Terminated Particulate / foreign matter Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-247-97 D-1281-2020
Class III · Low risk

Gabapentin Tablets USP

Failed Impurities/Degradation Specifications; failure of Impurity A test at the 12-month long-term stability testing.

Terminated Impurity / degradation InvaGen Pharmaceuticals, Inc. NDC 76282-405-05 D-1272-2020
Class III · Low risk

Fentanyl Citrate Injection

Failed impurities/degradation specification: Out-of-Specification result for total impurity at 4.1% (Limit: NMT 3.0%) during retained sample testing.

Terminated Impurity / degradation Akorn Inc NDC 17478-030-02 D-1258-2020
Class III · Low risk

Tacrolimus Capsules

Presence of foreign tablet/capsule - Potential presence of commingled one Tacrolimus 1 mg capsule in 5 mg bottles.

Terminated Particulate / foreign matter Mylan Pharmaceuticals Inc. NDC 0378-2047-01 D-1057-2020
Class III · Low risk

Bekyree

Failed Content Uniformity Specifications: Out Of Specification test results observed for content and blend uniformity.

Terminated Wrong potency / content Lupin Pharmaceuticals Inc. NDC 68180-879-11 D-1055-2020
Class III · Low risk

PrediniSONE Tablets

Labeling: Incorrect or Missing Exp Date - An incorrect expiration date has been identified on Prednisone Tablets USP 5 mg

Terminated Labeling / mix-up Par Pharmaceutical Inc. NDC 0603-5337-31 D-1035-2020
Class III · Low risk

Quetiapine Fumarate Extended-Release Tablets

Labeling; Incorrect or Missing Package Insert: Product was packaged with the package insert for Quetiapine Fumarate Tablets not Quetiapine Fumarate Extended-Release Tablets.

Terminated Labeling / mix-up The Harvard Drug Group D-1002-2020
Class III · Low risk

Quetiapine Fumarate Extended-Release Tablets

Labeling; Incorrect or Missing Package Insert: Product was packaged with the package insert for Quetiapine Fumarate Tablets not Quetiapine Fumarate Extended-Release Tablets.

Terminated Labeling / mix-up The Harvard Drug Group D-1001-2020
Class III · Low risk

Quetiapine Fumarate Extended-Release Tablets

Labeling; Incorrect or Missing Package Insert: Product was packaged with the package insert for Quetiapine Fumarate Tablets not Quetiapine Fumarate Extended-Release Tablets.

Terminated Labeling / mix-up The Harvard Drug Group D-1000-2020

Recalls by year